-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lysergic Acid Diethylamide in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lysergic Acid Diethylamide in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lysergic Acid Diethylamide in Generalized Anxiety Disorder...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delgocitinib in Hand Dermatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delgocitinib in Hand Dermatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delgocitinib in Hand Dermatitis Drug Details: Delgocitinib (Corectim) acts as anti-allergic agent....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pravibismane in Diabetic Foot Infection (DFI)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pravibismane in Diabetic Foot Infection (DFI) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pravibismane in Diabetic Foot Infection (DFI) Drug Details: Pravibismane (MBN-101)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QNIV in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QNIV in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QNIV in Influenza A Virus, H1N1 Subtype Infections...
-
Product Insights
Social Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Social Anxiety Disorder (SAD/Social Phobia) - Drugs In Development, 2023’, provides an overview of the Social Anxiety Disorder (SAD/Social Phobia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Social Anxiety Disorder (SAD/Social Phobia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Cluster Headache Syndrome (Cluster Headache) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cluster Headache Syndrome (Cluster Headache) - Drugs In Development, 2023’, provides an overview of the Cluster Headache Syndrome (Cluster Headache) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Cluster Headache), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Generalized Anxiety Disorder (GAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Generalized Anxiety Disorder (GAD) - Drugs In Development, 2023’, provides an overview of the Generalized Anxiety Disorder (GAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Generalized Anxiety Disorder (GAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Drugs In Development, 2023’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Autism Spectrum Disorder (ASD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Autism Spectrum Disorder (ASD) - Drugs In Development, 2023’, provides an overview of the Autism Spectrum Disorder (ASD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Major Depressive Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Major Depressive Disorder - Drugs In Development, 2023’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...